Efinaconazole
Azole Antifungal — DERMATOLOGICALS
Also known as: jublia, KP-103
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Efinaconazole is an ofp drug in the Azole Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2014. DrugCentral lists 1 molecular target, including Lanosterol 14-alpha demethylase. Recorded indications include Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes and Onychomycosis of toenails.
- Approval status: ofp (first approved 2014 by the FDA).
- Drug class: Azole Antifungal.
- Molecular targets: Lanosterol 14-alpha demethylase (1 listed in DrugCentral).
- Indications: Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes and Onychomycosis of toenails.
- ATC code: D01AC19 (Imidazole and triazole derivatives).
- Molecular formula: C18H22F2N4O; molecular weight 348.40 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Onychomycosis due to dermatophyte
- Onychomycosis due to Trichophyton mentagrophytes
- Onychomycosis of toenails
Mechanism & targets
| Established pharmacologic class | Azole Antifungal |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Lanosterol 14-alpha demethylase | — | inhibitor | — |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2014-07-04 | PMDA | — | — | |
| 2014-06-06 | FDA | — | DOW PHARM |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D01AC19 | DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Imidazole and triazole derivatives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Bronchopulmonary aspergillosis allergic | 489.5 |
| Blood calcium increased | 381.9 |
| Aspiration | 338.4 |
| Total lung capacity decreased | 334.3 |
| Blood test abnormal | 318.7 |
| Lung opacity | 317.0 |
| Pleuritic pain | 266.0 |
| Rales | 252.9 |
| Sputum discoloured | 240.2 |
| Transaminases increased | 230.3 |
| Bronchiectasis | 218.0 |
| Obstructive airways disorder | 197.9 |
Chemical structure
| Molecular formula | C18H22F2N4O |
|---|---|
| Molecular weight | 348.40 g/mol |
| CAS number | 164650-44-6 |
| InChIKey | NFEZZTICAUWDHU-RDTXWAMCSA-N |
| PubChem CID | 489181 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Efinaconazole used for?
DrugCentral lists the following indications for Efinaconazole: Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes and Onychomycosis of toenails.
How does Efinaconazole work?
Its molecular targets in DrugCentral include Lanosterol 14-alpha demethylase (inhibitor).
When was Efinaconazole first approved?
Efinaconazole was first approved by the FDA in 2014.
What drug class does Efinaconazole belong to?
Efinaconazole is in the Azole Antifungal class.
What is the chemical formula of Efinaconazole?
Efinaconazole has the molecular formula C18H22F2N4O and a molecular weight of 348.40 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4874 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2103877 — compound record and bioactivity
- PubChem CID 489181 — chemical identifiers
- DrugBank DB09040 — drug record
- FDA UNII J82SB7FXWB — substance identity
- DailyMed: FDA labels for Efinaconazole — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.